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CHAPTER I 
 
INTRODUCTION 
 
 Type II topoisomerases are ubiquitous enzymes that regulate levels of DNA 
under- and overwinding and remove knots and tangles from the genetic material (1-7). 
These enzymes are essential for cell survival and play vital roles in virtually every 
nucleic acid process, including DNA replication, transcription, and recombination. They 
also are required for proper chromosome organization and segregation (1-7). 
 Beyond their critical physiological functions, type II topoisomerases are the 
targets for a number of drugs that significantly impact human health (2, 8-12). The 
human type II enzymes (topoisomerase IIα and topoisomerase IIβ) are the targets for 
some of the most widely prescribed anticancer drugs in clinical use (2, 8-12). 
Furthermore, the bacterial type II enzymes (gyrase and topoisomerase IV) are the targets 
for quinolones, which are the most efficacious and broad-spectrum class of oral 
antibacterial agents used worldwide (13-20). 
 Given the importance of type II topoisomerases to eukaryotic and bacterial cells 
and to human health, it is critical to understand how these enzymes interact with their 
DNA substrates and with drugs. These are the issues that form the focus for this 
dissertation. 
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Type II Topoisomerases 
 
Catalytic Cycle  
 Type II topoisomerases regulate superhelical density and remove tangles and 
knots by the double-stranded DNA passage reaction depicted in Figure 1 (1, 3, 5, 6, 8, 
21-23). These enzymes require a divalent metal ion (Mg2+ appears to be the physiological 
ion) and ATP in order to carry out their complete catalytic cycle.  
 Type II enzymes bind two segments of DNA (Step 1). The first segment bound by 
the enzyme is the double helix that will be cleaved and is referred to as the “Gate-” or 
“G-segment.” The second segment is the double helix that will be transported through the 
transient DNA gate and is referred to as the “Transport-” or “T-segment.” DNA binding 
requires no cofactors. In the presence of the active site Mg2+ ions, type II topoisomerases 
sample the DNA for malleability (Step 2) (24). Sequences that can be cleaved are bent to 
an angle of ~150º (depending on the enzyme) (25). Conversely, sequences that cannot be 
bent are not cleaved (24, 26). DNA bending induces significant strain in the G-segment, 
which is maximal at the scissile bonds on either strand of the double helix. A double-
stranded break is generated in the G-segment (Step 3) using a noncanonical two-metal-
ion mechanism (22, 27, 28). The type II enzymes contain two active site tyrosyl residues 
(located on different subunits), each of which makes a single-stranded DNA break. The 
scissile bonds on the two strands of the double helix are staggered, and cleavage 
generates 5’-termini with four-base single-stranded cohesive ends.  During the scission 
event, type II topoisomerases covalently attach to the 5’-termini of the cleaved DNA. 
These covalent enzyme-cleaved DNA complexes are known as “cleavage complexes.” 
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Figure 1. Catalytic cycle of type II topoisomerases. The homodimeric enzyme is shown 
in blue, the DNA double helix that is cleaved and acts as the DNA gate (G-segment) is 
shown in green, and the double helix that is transported through the DNA gate (T-
segment) is shown in yellow. Details of the individual reaction steps are given in the text. 
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Two molecules of ATP are bound by the enzyme, which triggers the closing of the N-
terminal protein gate, the opening of the DNA gate, and the translocation of the T-
segment through the gate (Step 4). Although hydrolysis of the cofactor is not a 
prerequisite for DNA translocation, it appears that this step proceeds more rapidly if it is 
preceded by hydrolysis of one of the bound ATP molecules. The cleaved DNA is 
rejoined (Step 5), the T-segment is released through the C-terminal protein gate (Step 6), 
and, upon hydrolysis of the second ATP molecule, type II enzymes regain the ability to 
initiate a new round of catalysis (Step 7).  
 
Bacterial Type II Topoisomerases 
 Bacteria contain two distinct type II topoisomerases, gyrase and topoisomerase 
IV. Gyrase was discovered in 1976 (29). It was the first type II topoisomerase to be 
described and is the only enzyme in this class to retain its historical name. Gyrase is 
comprised of two distinct subunits, GyrA and GyrB (~96 kDa and ~88 kDa, respectively) 
(Figure 2) and functions as an A2B2 tetramer (1, 3, 6, 7, 21). GyrA contains the active site 
tyrosyl residue that forms the covalent bond with DNA during scission, and GyrB 
contains consensus sequences for ATP binding.  
 Of the known type II topoisomerases, gyrase is the only enzyme that is capable of 
generating negative supercoils in the double helix without the assistance of additional 
DNA binding proteins or intercalators (1, 3, 6, 7, 21, 23). Gyrase accomplishes this feat 
by using a sign inversion mechanism (3, 7, 23, 30). The enzyme wraps the double helix 
around itself in a right-handed fashion such that it generates a constrained positive 
supercoil and a compensatory unconstrained negative supercoil. The C-terminal domain 
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Figure 2. Domain structures of type II topoisomerases. Bacterial (E. coli gyrase and 
topoisomerase IV) and eukaryotic (human topoisomerase IIα and IIβ) type IIA enzymes 
are shown. Regions of homology among the enzymes are indicated by colors. The N-
terminal (i.e., GyrB/ParE) homology domains (yellow) contain the regions responsible 
for ATP binding and hydrolysis. The central (i.e., GyrA/ParC) homology domains (blue) 
contain the active site tyrosyl residue that performs cleavage and ligation (C-L) and 
forms the covalent bond with DNA during scission. The variable C-terminal domains are 
shown in green for the bacterial enzymes and in red for the eukaryotic enzymes. These 
domains are involved in DNA topology sensing during the strand passage reaction. 
Subunits and domains are drawn proportionally to their length. The active site tyrosyl 
residue is indicated for each enzyme. 
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of the GyrA subunit, which adopts a unique DNA bending β-pinwheel conformation (31), 
is required for this chiral DNA wrapping event. As a result of the double-stranded DNA 
passage event, gyrase converts the positive supercoil to a negative supercoil.  
 Because of the intramolecular DNA wrapping mechanism used by gyrase, its 
ability to generate negative supercoils in the double helix is much more efficient than its 
ability to untangle or unknot the genetic material (which often requires an intermolecular 
interaction between separate DNA molecules) (1, 3, 6, 7, 21, 23). Consequently, the 
major physiological roles of DNA gyrase stem directly from its ability to underwind the 
double helix. DNA gyrase plays a critical role in opening DNA replication origins and 
removing positive supercoils that accumulate in front of replication forks and 
transcription complexes. In addition, because prokaryotes lack the highly organized 
chromatin structure that helps regulate supercoiling in eukaryotes, gyrase works in 
conjunction with the ω protein (a type IA topoisomerase that removes negative supercoils 
from the double helix) to set and maintain the global superhelical density in bacterial 
cells. 
 The second bacterial type II topoisomerase, topoisomerase IV, was discovered in 
1990 (1, 3, 6, 7, 21, 23). Like gyrase, this enzyme is an A2B2 tetramer (Figure 2). The two 
subunits of topoisomerase IV were first identified in Gram-negative species as proteins 
required for chromosome partitioning and were designated ParC (~88 kDa) and ParE 
(~70 kDa). Based on sequence analysis, it was determined that the ParC and ParE 
proteins were homologous to the A and B subunits of gyrase, respectively. Subsequent 
functional studies led to the discovery that the ParC/ParE complex constituted a novel 
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type II topoisomerase. In Gram-positive species, the subunits of topoisomerase IV are 
designated as gyrase-like proteins, GrlA and GrlB, respectively.  
 Despite the homology between topoisomerase IV and gyrase, the two enzymes 
display distinct properties that affect their physiological functions (1, 3, 6, 7, 21, 23). 
First, there are critical differences between the C-terminal domains of ParC/GrlA and 
GyrA. Instead of maintaining the “closed” β-pinwheel conformation seen in gyrase (31), 
this region of topoisomerase IV adopts an “open” conformation (32). This “broken” 
pinwheel cannot perform the chiral wrapping function that is necessary for the gyrase 
supercoiling reaction. Consequently, topoisomerase IV can remove positive and negative 
supercoils from DNA but cannot actively underwind the double helix. Rather, the C-
terminal domain of topoisomerase IV functions as a topology sensor that allows the 
enzyme to distinguish the handedness of DNA supercoils. As a result, topoisomerase IV 
is able to remove positive DNA supercoils (like those found ahead of replication forks) 
much more efficiently than it does negative supercoils (33, 34). This ability has led to 
speculation that topoisomerase IV may act ahead of DNA tracking systems to help gyrase 
alleviate overwinding of the double helix. However, the precise role of topoisomerase IV 
in this process has yet to be defined. 
 Second, because topoisomerase IV does not utilize the intramolecular chiral DNA 
wrapping mechanism of gyrase, it is much more efficient at catalyzing intermolecular 
reactions (i.e., those that require actions on two separate DNA molecules) (1, 3, 6, 7, 21, 
23). Thus, the ability of topoisomerase IV to resolve DNA tangles and knots is much 
more efficient than that of gyrase. As a result, the most important cellular functions of 
topoisomerase IV are the unlinking of daughter chromosomes following DNA replication 
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and the removal of DNA knots that are formed during recombination and other 
physiological processes. 
 
Eukaryotic Type II Topoisomerases 
 The eukaryotic type II enzyme, topoisomerase II, was discovered in 1980 (1, 3, 6, 
7, 21, 23). Like bacterial topoisomerase IV, topoisomerase II can remove supercoils from 
the double helix and can resolve DNA tangles and knots. Eukaryotes encode no “gyrase-
equivalent” topoisomerase that is able to actively underwind DNA. The supercoiling 
activity of gyrase has been obviated by the evolution of histones. Because nucleosomes 
wrap the genetic material in a left-handed superhelix (which underwinds the DNA), 
removal of the resulting compensatory positive supercoils by a non-gyrase topoisomerase 
leads to a net negative supercoiling of the eukaryotic genome (30). 
 Eukaryotic species such as yeast and Drosophila encode only a single type II 
topoisomerase (i.e., topoisomerase II). However, vertebrates express two isoforms, 
topoisomerase IIα and topoisomerase IIβ (1, 3, 4, 6, 8, 21, 22, 35). These two isoforms 
share extensive amino acid sequence identity (~70%) but are encoded by separate genes 
(located at chromosomal bands 17q21-22 and 3p24 in humans, respectively). 
Topoisomerase IIα and topoisomerase IIβ also can be distinguished by their protomer 
molecular masses (~170 kDa and ~180 kDa, respectively).  
 Eukaryotic type II topoisomerases are homologous to the bacterial type II 
enzymes (Figure 2) (1, 3, 4, 6, 8, 21, 22, 35). However, the two subunits have fused into a 
single polypeptide, and the eukaryotic enzymes function as homodimers (as opposed to 
an A2B2 tetramer). On the basis of amino acid sequence comparisons with bacterial 
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gyrase, each topoisomerase II protomer can be divided into three distinct domains (Figure 
2). The N-terminal domain of the enzyme is homologous to GyrB and contains the 
binding site for ATP. The central domain is homologous to much of GyrA and contains 
the active site tyrosyl residue. The C-terminal domain of topoisomerase II, which 
occupies the same location on the protein as the C-terminal domain of GyrA/ParC/GrlA, 
is highly variable. This region shares little to no sequence similarity to the equivalent 
region in DNA gyrase or topoisomerase IV and differs considerably between type II 
topoisomerases, even across eukaryotic species. The C-terminal domain of eukaryotic 
topoisomerase II contains nuclear localization sequences as well as amino acid residues 
that interact with cellular components or are phosphorylated in vivo.  
 It is not obvious why vertebrates encode two distinct topoisomerase II isoforms. 
In contrast to gyrase and topoisomerase IV, enzymological differences between 
topoisomerase IIα and topoisomerase IIβ are subtle (1, 3, 4, 6, 8, 21, 22). In this regard, 
the only major characteristic that distinguishes topoisomerase IIα and topoisomerase IIβ 
is the ability to recognize the handedness of DNA supercoils (36). While the α isoform 
removes positive DNA supercoils ~10–fold faster than it does negative, the β isoform 
removes both at similar rates. As with topoisomerase IV, this topology sensing function 
of topoisomerase IIα is embodied in the C-terminal domain of the protein. 
 Topoisomerase II plays a number of essential roles in eukaryotic cells and 
participates in virtually every major process that involves movement or organization of 
the genetic material (1, 3, 4, 6, 8, 21, 22, 35). The enzyme unlinks tangled daughter 
chromosomes following replication and resolves DNA knots that are formed during 
recombination. It also helps to alleviate the torsional stress that accumulates ahead of 
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replication forks and transcription complexes. Topoisomerase II is required for proper 
chromosome condensation, cohesion, and segregation and appears to play roles in 
centromere function and chromatin remodeling. Finally, the enzyme is important for the 
maintenance of proper chromosome organization and structure and is the major non-
histone protein of the mitotic chromosome scaffold and the interphase nuclear matrix. 
 Topoisomerase IIα and topoisomerase IIβ have distinct patterns of expression and 
separate nuclear functions (1, 3, 4, 6, 8). Topoisomerase IIα is essential for the survival 
of proliferating cells and is regulated over cell and growth cycles. Enzyme levels increase 
throughout S-phase of the cell cycle and peak at the G2/M boundary. Although 
topoisomerase IIα is nearly non-existent in quiescent or differentiated tissues, rapidly 
proliferating cells contain as many as ~500,000 copies of the enzyme. Topoisomerase IIα 
is associated with replication forks, and its ability to preferentially relax positive 
supercoils (36) has led to speculation that it helps remove torsional stress ahead of the 
replication machinery. Furthermore, the enzyme remains tightly bound to chromosomes 
during mitosis. In light of the enzymological characteristics, regulation, and cell biology 
described above, it is believed that topoisomerase IIα is the isoform that functions in 
growth-related cellular processes (1, 3, 4, 6, 8). 
 Topoisomerase IIβ is dispensable at the cellular level, and its presence cannot 
compensate for the loss of topoisomerase IIα in mammalian cells (1, 3, 4, 6, 8, 37). 
However, the β isoform is required for proper neural development in mice (38). In 
contrast to topoisomerase IIα, the concentration of topoisomerase IIβ is independent of 
the cell cycle, and high levels of this isoform are found in most cell types regardless of 
proliferation status (1, 3, 4, 6, 8, 37). Topoisomerase IIβ dissociates from chromosomes 
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during mitosis. The sequences that govern the association/dissociation of topoisomerase 
II with mitotic chromosomes reside in the C-terminal domain (39). Ultimately, the 
physiological functions of the β isoform have yet to be fully defined. However, recent 
evidence suggests that topoisomerase IIβ plays an important role in the transcription of 
hormonally- or developmentally-regulated genes (40). 
 
Type II Topoisomerases as Cellular Toxins 
 Because type II topoisomerases must generate double-stranded DNA breaks prior 
to strand passage, they are inherently dangerous proteins. Thus, while necessary for cell 
viability, these enzymes also have the capacity to fragment the genome (2, 5-11). As a 
result of this “Jekyll-Hyde” persona, levels of cleavage complexes must be maintained in 
a critical balance (Figure 3).  
 Cleavage complexes are requisite intermediates in the strand passage reaction 
catalyzed by type II topoisomerases. Thus, a decrease in their concentration generally 
reflects a decrease in overall catalytic activity. Consequently, if cleavage complexes drop 
below threshold levels, topoisomerase IIα and gyrase are unable to maintain necessary 
rates of DNA replication and topoisomerase IIα and topoisomerase IV are unable to 
completely disentangle daughter chromosomes following replication. Consequently, cells 
die as a result of mitotic failure.  
 Conversely, if levels of cleavage complexes generated by gyrase or topoisomerase 
IV in bacteria or topoisomerase IIα or topoisomerase IIβ in eukaryotes increase, cells also 
suffer catastrophic physiological effects, but for different reasons (2, 3, 8-11, 41). When 
replication forks, transcription complexes, or other DNA tracking systems attempt to 
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Figure 3. Type II topoisomerases are essential but genotoxic enzymes. The balance 
between enzyme-mediated DNA cleavage (which is required for their physiological 
functions) and ligation is critical for the survival of bacterial and eukaryotic cells. If the 
level of enzyme–mediated DNA cleavage decreases below threshold levels, cells are not 
able to untangle daughter chromosomes and ultimately die of mitotic failure (left). If the 
level of cleavage becomes too high (right), the actions of DNA tracking systems can 
convert transient cleavage complexes to permanent double-stranded breaks. The resulting 
DNA breaks, as well as the inhibition of essential DNA processes, initiate recombination/ 
repair pathways and can generate chromosome translocations and other DNA aberrations. 
If the strand breaks overwhelm the cell, they can trigger cell death. This is the basis for 
the actions of several widely prescribed anticancer and antibacterial drugs. If cell death 
does not occur, mutations or chromosomal aberrations may be present in surviving 
populations. Exposure of human cells to topoisomerase II poisons is associated with the 
formation of specific types of t-AMLs and infant leukemias that involve the MLL (mixed 
lineage leukemia) gene at chromosome band 11q23 and t-APLs that feature t(15:17) 
chromosomal translocations between the PML (promyelocytic leukemia) and RARA 
(retinoic acid receptor α) genes (lower right arrow). The specific type II topoisomerases 
involved in the individual cellular processes described above are indicated in green. 
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traverse the covalent topoisomerase-DNA “roadblock,” accumulated cleavage 
intermediates are converted to strand breaks that are no longer tethered by protein-linked 
bridges. The ensuing damage induces recombination/repair pathways that can trigger 
mutations, chromosomal translocations, or other aberrations. If the DNA breaks 
overwhelm the repair process, their presence can initiate cell death pathways. However, if 
cells recover sufficiently, they may survive but contain damaged chromosomes. In some 
cases, chromosome aberrations may initiate a leukemogenic transformation in humans (2, 
8, 42-47).  
 
Topoisomerase II Poisons 
 Chemicals that increase levels of topoisomerase II-DNA cleavage complexes 
convert the enzyme to a potent cellular toxin that generates the chromosomal damage 
described above. These compounds are called topoisomerase II poisons to distinguish 
them from catalytic inhibitors of the enzyme (2, 8-11). Topoisomerase II poisons kill 
cells by a gain of function, inducing the enzyme to generate DNA strand breaks, as 
opposed to robbing the cell of the essential functions of the enzyme.  
This section will focus on poisons that affect the human type II topoisomerases, 
topoisomerase IIα and topoisomerase IIβ. Quinolones, which poison the bacterial type II 
enzymes, gyrase and topoisomerase IV, are discussed in the following section. 
 Based on their mechanism of action, topoisomerase II poisons can be categorized 
into two distinct classes, “interfacial poisons” and “covalent poisons” (2, 8, 10, 11, 48). 
Selected topoisomerase II poisons are shown in Figure 4. The characteristics and 
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Figure 4. Structures of selected topoisomerase II poisons that target the eukaryotic type II 
enzymes. Clinically used anticancer drugs that target topoisomerase II are shown on the 
left. Dietary topoisomerase II poisons are shown on the right. The catechol and quinone 
metabolites of etoposide (generated by CYP3A4 and cellular oxidases or redox cycling, 
respectively) are highlighted in the red box. Epigallocatechin gallate is abbreviated as 
EGCG. 
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distinguishing features of the two classes of topoisomerase II poisons are described in 
Figure 5. 
Interfacial poisons bind non-covalently to the cleavage complex at the protein-
DNA interface. They intercalate into the double helix at the cleaved scissile bond and 
impede the ability of topoisomerase II to rejoin the DNA ends (8, 10, 11, 49). In essence, 
interfacial poisons act as “molecular doorstops” and prevent the DNA gate from being 
closed. Examples, including etoposide, doxorubicin, mitoxantrone, and bioflavonoids 
such as genistein, are shown in Figure 4. 
 Covalent poisons function distal to the active site of topoisomerase II (2, 8, 48). 
They contain reactive groups such as quinones or maleiamides and covalently adduct to 
cysteine (and potentially other amino acid) residues (48, 50-53). It is believed that 
covalent poisons increase levels of enzyme-mediated DNA cleavage by altering the 
conformation of the topoisomerase II N-terminal protein gate. Examples, including 
epigallocatechin gallate (EGCG) (54), which is prevalent in green tea, and curcumin (55), 
which is the major flavor and aromatic component in turmeric, are shown in Figure 4. 
 Covalent topoisomerase II poisons are found in a number of fruits, vegetables, 
and other plants that are common components in the human diet (48, 50, 53). Many of 
these foods, such as green tea and soy, are believed to have chemopreventative properties 
(48, 56). Covalent topoisomerase II poisons are also prevalent in medicinal herbs, such as 
turmeric and black seed (55, 57). 
 Topoisomerase II poisons represent some of the most important and widely 
prescribed anticancer drugs worldwide (2, 8-11, 48). At the present time, six of these 
agents are approved for use in the United States. Topoisomerase II-targeted drugs 
16 
 
 
 
 
 
 
 
Figure 5. Properties of interfacial and covalent topoisomerase II poisons. 
17 
 
encompass a diverse group of natural and synthetic compounds and are used to treat a 
variety of human malignancies (2, 8-11, 48). For example, etoposide and doxorubicin 
(and its derivatives) are front-line therapies for a myriad of systemic cancers and solid 
tumors, including leukemias, lymphomas, sarcomas, breast cancers, lung cancers, 
neuroblastoma, and germ-cell malignancies. Furthermore, mitoxantrone is used to treat 
breast cancer, acute myeloid leukemia, and non-Hodgkin lymphoma. In addition, it is 
used as a single agent to treat multiple sclerosis. 
 All clinically relevant topoisomerase II-targeted anticancer drugs act as interfacial 
poisons. Furthermore, they all affect the activities of both enzyme isoforms. However, the 
degree to which topoisomerase IIα and IIβ are targeted by any given drug and the relative 
contributions of the two isoforms to drug efficacy are not well understood (2, 8-11, 48). 
Although some drugs “prefer” one isoform over the other, no truly topoisomerase IIα- or 
topoisomerase IIβ-specific drugs are available for clinical use at the present time (12). 
 
Quinolone Antibacterials 
 Bacterial DNA gyrase and topoisomerase IV are the targets for quinolone-based 
antibacterial agents (13-20). Structures of selected quinolones are shown in Figure 6. 
Quinolones are an extremely successful drug family and are widely prescribed for 
the prophylaxis and treatment of infections in humans. Members of this drug class 
include the most active and most broad-spectrum oral antibacterials currently in clinical 
use. These agents are effective against a variety of pathogens, including Gram-negative 
and Gram-positive species (13-20).  
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Figure 6. Structures of selected quinolone antibacterial agents that target gyrase and 
topoisomerase IV. The figure shows the first generation quinolones nalidixic acid and 
oxolinic acid, the second-generation fluoroquinolones norfloxacin and ciprofloxacin, and 
the newer generation fluoroquinolones levofloxacin and moxifloxacin. Quinolone 
numbering is given on the structure of nalidixic acid. 
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 In parallel to the effects of anticancer drugs on human topoisomerases, quinolones 
increase levels of gyrase- and topoisomerase IV-DNA cleavage complexes (in large part) 
by inhibiting enzyme-mediated ligation of cleaved DNA (19, 58-60). Recently generated 
crystal structures provide strong evidence that these drugs contact both the protein and 
the DNA in the ternary complex and block ligation by intercalating into the double helix 
at the cleaved scissile bond (Figure 7) (61).  
 The founding quinolone, nalidixic acid (Figure 6), was first synthesized in the 
early 1960s (14, 18). This compound, along with the other early generation quinolones 
(such as oxolinic acid), was introduced into clinics throughout that decade for the 
treatment of urinary tract infections. Ultimately, these first-generation quinolones were 
dropped from clinical use due to their limited efficacy.  
 By the early 1980s, advancements in quinolone chemistry resulted in the 
development of second-generation compounds with considerably improved activity and 
pharmacokinetics (13-20). The most critical change was the introduction of a fluorine 
atom at the C-6 position (Figure 6). This alteration dramatically enhanced potency 
against gyrase and promoted drug uptake by the bacterial cell. The first clinically 
important “fluoroquinolone” was norfloxacin (Figure 6). It displayed much greater 
activity against Gram-negative bacteria than did earlier quinolones and also exhibited 
modest activity against some Gram-positive species. Due to poor tissue distribution and 
low serum levels, norfloxacin was restricted to the treatment of urinary tract infections 
and sexually transmitted diseases. Subsequent fluoroquinolones (Figure 6), such as 
ciprofloxacin, were the first family members to display clinical activity outside of the 
urinary tract. Ciprofloxacin is used to treat a variety of Gram-negative (and, to a lesser 
20 
 
 
Figure 7. Crystal structure of a moxifloxacin-stabilized Acinetobacter baumannii 
topoisomerase IV-DNA cleavage complex. The catalytic core of the enzyme is shown. 
Moxifloxacin is shown in red, the topoisomerase IV A and B subunits are shown in blue 
and green, respectively, and DNA is shown in yellow. Top: A top view of the cleavage 
complex showing two quinolone molecules intercalating four base pairs apart at the sites 
of DNA cleavage. Bottom: A front view (rotated by 90° from the top view) of the 
cleavage complex. Protein Data Bank accession 2XKK was visualized using Discovery 
Studio 3.5 Visualizer (Accelrys Software Inc.). Adapted from Wohlkonig et al. (61).  
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extent, Gram-positive) pathogens and has come to worldwide attention as the drug of 
choice for the treatment of anthrax.  
 Recently, newer generations of quinolones have emerged that display markedly 
higher activity against Gram-positive bacteria (13-20). Drugs such as levofloxacin and 
moxifloxacin (Figure 6) also display excellent activity against Gram-positive respiratory 
tract infections and have greatly extended the clinical range of this drug class.  
 
Quinolone Targeting 
 Gyrase was first identified as the toxic target for quinolones in Escherichia coli in 
1977 (62, 63). The discovery that the ParC/ParE subunits constituted topoisomerase IV 
raised the question of whether this topoisomerase also was a target for quinolones (64). 
Most subsequent studies concur that both enzymes are targets for quinolones in bacterial 
cells (17, 65). However, the relative contributions of gyrase and topoisomerase IV to drug 
efficacy are not well understood. Early studies suggested that gyrase rather than 
topoisomerase IV was the primary cytotoxic target for quinolones in Gram-negative 
bacteria, but that the opposite was true in Gram-positive species (14). However, recent 
studies indicate that this paradigm does not hold in all cases and that the issue of 
quinolone targeting needs to be evaluated on a strain-by-strain and drug-by-drug basis 
(17, 19). 
 
Quinolone Resistance and Enzyme Interactions 
 Resistance to antibacterial agents has become an increasingly important clinical 
issue (17-19, 65). Unfortunately (due in part to overuse), quinolone resistance is 
22 
 
becoming more prevalent. Although increased levels of multidrug efflux pumps often 
play a role in cases of high resistance, initial resistance to quinolones is usually 
associated with point mutations in the DNA cleavage-ligation subunits of gyrase (GyrA) 
and/or topoisomerase IV (ParC/GrlA). 
 The two most common mutations associated with quinolone resistance occur at 
Ser83 and Glu87 of GyrA (sequence numbering is based on E. coli GyrA) or the 
homologous residues of ParC/GrlA (17-19, 65). The enzyme in which a mutation occurs 
first is defined as the primary target for quinolones in a given bacterial species. This event 
generally confers <10–fold resistance. Subsequent mutation of the second enzyme often 
confers an additional order of magnitude of quinolone resistance. 
 Quinolone resistance is associated with a decreased affinity of gyrase or 
topoisomerase IV for the drug as well as a decreased ability of the drug to induce stable 
cleavage complexes and inhibit DNA ligation (18, 19, 66). Recent structural and 
biochemical evidence indicates that the basis for Ser83/Glu87-mediated resistance is 
related to the ability of quinolones to bind divalent metal ions (Figure 8) (19, 60, 61, 66-
68). The primary interaction of clinically relevant quinolones with gyrase and 
topoisomerase IV is coordinated through this metal ion via four water molecules, two of 
which are anchored by Ser83 and Glu87. Thus far, the presence of the water-metal ion 
bridge and its role in mediating interactions with clinically relevant quinolones has been 
demonstrated in topoisomerase IV. Although mutagenesis studies in gyrase are consistent 
with a critical role for the water-metal ion bridge, the existence of the bridge has yet to be 
demonstrated in gyrase.  
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Figure 8. Quinolone-topoisomerase IV binding is mediated by a water-metal ion bridge. 
Left: Crystal structure of a moxifloxacin-stabilized Acinetobacter baumannii topoisomer-
ase IV-DNA cleavage complex. Moxifloxacin is shown in black and the non-catalytic 
Mg2+ ion that is chelated by the C3/C4 keto acid of the quinolone and participates in the 
bridge is shown in green. The four water molecules that fill out the coordination sphere of 
the Mg2+ ion are shown in blue. The backbone of selected portions of the protein amino 
acid chain is shown in yellow. The side chains of the serine and acidic residues that form 
hydrogen bonds with the water molecules in the water-metal ion bridge are shown in red. 
For clarity, DNA has been omitted from the picture. Protein Data Bank accession 2XKK 
was visualized using Discovery Studio 3.5 Visualizer (Accelrys Software Inc.). Adapted 
from Wohlkonig et al. (61) Right: Simplified diagram of the water-metal ion bridge 
adapted from Aldred et al. (19). A generic quinolone is in black, the non-catalytic Mg2+ is 
orange, water molecules are blue, and the coordinating serine and acidic residues (B. 
anthracis topoisomerase IV numbering) are red and green, respectively. Blue dashed 
lines indicate the octahedral coordination sphere of the divalent metal ion. The red or 
green dashed lines represent hydrogen bonds between the serine side chain hydroxyl 
group or the acidic residue side chain carboxyl group and the water molecules. Bottom: 
Sequence alignment of the A subunits showing the serine and acidic residues (red) that 
coordinate the water-metal ion bridge. Sequences of A. baumannii (Ab), Bacillus 
anthracis (Ba), Escherichia coli (Ec), Staphylococcus aureus (Sa), and Streptococcus 
pneumoniae (Sp) gyrase (GyrA) and topoisomerase IV (ParC/GrlA) are shown. The 
homologous regions of human topoisomerase IIα (hTIIα) and IIβ (hTIIβ), which lack the 
residues necessary to coordinate the water-metal ion bridge interaction, are shown for 
comparison.
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Scope of the Dissertation 
 Because of the importance of type II topoisomerases to nucleic acid functions in 
human and bacterial cells and because of the wide use of anticancer and antibacterial 
agents that target these enzymes, it is important to understand how type II topoisomerases 
interact with it DNA substrate and with drugs. Therefore, the goals of this dissertation are 
to further our understanding of how human and bacterial type II topoisomerases interact 
with DNA and discern the handedness of DNA supercoils, how human topoisomerase IIα 
interacts with covalent poisons, and how bacterial gyrase interacts with quinolone 
antibacterials. 
 An introduction to bacterial and human type II topoisomerases, topoisomerase II 
poisons, and quinolone antibacterials is presented in Chapter I.  
 Chapter II describes the characterization of the catalytic core of human 
topoisomerase IIα. Results further define the distinct contributions of the N-terminal gate 
and the catalytic core to topoisomerase II function. The work demonstrates that the 
catalytic core senses the handedness of DNA supercoils during cleavage, while the N-
terminal gate is critical for capturing the transport-segment and for the activity of 
covalent poisons. These findings have been published (69). 
 Chapter III describes the ability of Bacillus anthracis gyrase to discern the 
handedness of DNA supercoils during DNA cleavage. Results also lay the groundwork 
for future studies on assessing the role of the water-metal ion bridge in mediating 
interactions between gyrase and clinically relevant quinolones. 
 Concluding remarks on the research presented in this dissertation are provided in 
Chapter IV. 
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CHAPTER II 
 
THE CATALYTIC CORE OF HUMAN TOPOISOMERASE IIα: INSIGHTS INTO 
ENZYME–DNA INTERACTIONS AND DRUG MECHANISM 
 
Introduction 
 As discussed in the previous chapter, eukaryotic type II topoisomerases function 
as homodimeric proteins. On the basis of homology with DNA gyrase, these enzymes can 
be divided into three domains: the N-terminal domain, the catalytic core, and the C-
terminal domain (4-8, 70). The N-terminal domain contains the site of ATP binding and 
hydrolysis. ATP binding triggers dimerization of the N-terminal domain, which helps 
capture the T-segment and closes the N-terminal protein gate (71). This action induces 
the transport of the T-segment passage through the open gate in the G-segment (4-8, 70, 
71). The catalytic core of topoisomerase II contains the active site tyrosine that cleaves 
and covalently attaches to the DNA. It also forms a second protein gate that allows the T-
segment to exit the enzyme following strand passage. The C-terminal domain is the least 
understood portion of topoisomerase II. It is highly variable and contains nuclear 
localization sequences and sites of phosphorylation (2, 7, 8). Although it is not necessary 
for catalytic activity, the C-terminal domain is involved in the recognition of DNA 
geometry during strand passage and provides different type II topoisomerases with unique 
capabilities. In human topoisomerase IIα, the C-terminal domain allows the enzyme to 
relax positively supercoiled (i.e., overwound) DNA that accumulates ahead of replication 
forks ten times faster than it does negatively supercoiled (i.e., underwound) molecules 
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(36, 72). In contrast, topoisomerase IIβ relaxes positive and negative DNA supercoils at 
the same rate (36, 72).  
 Although only topoisomerase IIα is able to recognize the handedness of DNA 
supercoils during relaxation, both isoforms are able to distinguish between positive and 
negative supercoils during DNA cleavage (73). Topoisomerase IIα and topoisomerase IIβ 
maintain higher levels of cleavage complexes with underwound as compared to 
overwound molecules. In spite of the important role played by the C-terminal domain in 
distinguishing DNA geometry during relaxation, this portion of the enzyme is not 
involved in recognizing supercoil handedness during DNA cleavage (72). It is not 
obvious which domain of topoisomerase II is responsible for this recognition. Given the 
role of the N-terminal gate in capturing the T-segment and that of the catalytic core in 
cleaving the G-segment, both are likely candidates.  
 In addition, despite the suggested role of the N-terminal gate in the actions of 
covalent poisons (74, 75), the portion of topoisomerase II that mediates the effects of 
these compounds has not been established. Further complicating this issue, covalent 
poisons have been shown to adduct cysteine residues in both the N-terminal gate and the 
catalytic core of topoisomerase IIα (51, 53).  
 To address the above issues, the DNA cleavage activity of the catalytic core of 
human topoisomerase IIα was characterized. Results indicate that the catalytic core is 
sufficient for the enzyme to recognize DNA supercoil handedness during the cleavage 
reaction. However, the catalytic core alone displayed little ability to cleave DNA 
substrates that did not intrinsically provide the enzyme with a transport segment (i.e., 
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substrates that did not contain crossovers). Finally, the N-terminal gate is necessary for 
cleavage enhancement by covalent poisons. 
 
Experimental Procedures  
 
Enzymes  
The truncated hTop2α∆1175 (containing amino acids 1-1175) was constructed as 
described previously (76). Human topoisomerase IIα and hTop2α∆1175 were expressed 
in S. cerevisiae JEL-1∆top1 and purified as described by Kingma et al. (77). The 
catalytic core of human topoisomerase IIα (containing residues 431-1193) (78) was 
expressed in yeast cells and purified using a Ni2+-nitriloacetic acid agarose column 
(Qiagen) as described previously (79, 80). The enzyme was stored at -80 °C as a 1.5 
mg/mL stock in 50 mM Tris-HCl, pH 7.8, 0.1 mM EDTA, 750 mM KCl, 5% glycerol. 
For all of the enzymes examined, the concentration of dithiothreitol carried over from 
purification protocols was <2 µM in final reaction mixtures. 
 
DNA Substrates 
 Negatively supercoiled pBR322 plasmid DNA was prepared using a Plasmid 
Mega Kit (Qiagen) as described by the manufacturer. Positively supercoiled pBR322 
DNA was prepared by treating negatively supercoiled molecules with recombinant 
Archaeoglobus fulgidus reverse gyrase (36, 81). The number of positive supercoils was 
comparable to the number of negative supercoils in the original pBR322 preparations 
(36). For experiments comparing positively and negatively supercoiled DNA, the 
negatively supercoiled plasmid was processed identically to the positively supercoiled 
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molecules except that reverse gyrase was omitted from reaction mixtures. Relaxed 
pBR322 plasmid DNA was generated by treating negatively supercoiled pBR322 with 
topoisomerase I and purified as described previously (67). 
 
Drugs 
 Etoposide, benzoquinone, and thymoquinone were purchased from Sigma-
Aldrich. Etoposide was stored at room temperature as a 20 mM solution in 100% DMSO. 
Benzoquinone was stored at -20 °C as a 20 mM solution in water. Thymoquinone was 
stored at 4 °C as a 40 mM solution in 100% DMSO. The quinolone CP-115,953 was the 
gift of Thomas D. Gootz and Paul R. McGuirk (Pfizer). It was stored at -20 °C as a 40 
mM solution in 0.1 N NaOH and was diluted five-fold with 10 mM Tris–HCl (pH 7.9) 
immediately prior to use. Etoposide quinone was synthesized as described previously 
(82-84) and was stored at 4 °C as a 20 mM solution in 100% DMSO. 
 
Plasmid DNA Cleavage 
DNA cleavage reactions were carried out using the procedure of Fortune and 
Osheroff (85). Reaction mixtures contained 10 nM pBR322 and 150 nM wild-type 
topoisomerase IIα, 80 nM hTop2α∆1175, or 430 nM catalytic core in a total of 20 µL of 
cleavage buffer [10 mM Tris-HCl (pH 7.9), 5 mM MgCl2, 100 mM KCl, 0.1 mM EDTA, 
and 2.5% (v/v) glycerol]. Reaction mixtures were incubated at 37 °C for 6 min, and 
enzyme−DNA cleavage complexes were trapped by the addition of 2 μL of 5% SDS 
followed by 2 μL of 250 mM EDTA (pH 8.0). Proteinase K (2 μL of a 0.8 mg/mL 
solution) was added, and samples were incubated at 45 °C for 30 min to digest the 
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enzyme. Samples were mixed with 2 µL of agarose loading dye [60% sucrose in 10 mM 
Tris-HCl (pH 7.9), 0.5% bromophenol blue, and 0.5% xylene cyanol FF], heated at 45 °C 
for 2 min, and subjected to electrophoresis in 1% agarose gels in 40 mM Tris-acetate (pH 
8.3) and 2 mM EDTA containing 0.5 μg/mL ethidium bromide. DNA bands were 
visualized by UV light and quantified using an Alpha Innotech digital imaging system. 
DNA cleavage was monitored by the conversion of supercoiled plasmid to linear 
molecules. 
 Note that lower levels of hTop2α∆1175 were used in reaction mixtures because in 
the presence of Mg2+, the protein displays ~2–fold higher levels of DNA cleavage than 
does wild-type topoisomerase IIα (76). Conversely, higher levels of the catalytic core 
were used because it displays lower levels of baseline DNA cleavage than does the wild-
type enzyme in reactions containing Mg2+ (see Figure 10). 
 DNA cleavage reactions were carried out in the presence of 0–250 µM etoposide, 
0–20 µM CP–115,953, or 0–100 µM benzoquinone, thymoquinone, or etoposide 
quinone. Alternatively, MgCl2 was omitted from the cleavage buffer and reaction 
mixtures contained 0–5 mM CaCl2. 
 
DNA Cleavage Site Utilization 
DNA cleavage sites were mapped using a modification (86) of the procedure of 
O’Reilly and Kreuzer (87). A unique derivative of pUC19 (pMP-bcr6) was used as 
substrate for DNA cleavage site utilization experiments. The substrate was generated by 
modifying pUC19 to include a region of PML intron 6 that contains an established 
breakpoint associated with therapy-related acute promyelocytic leukemia. The genomic 
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DNA of human CEM cells was prepared using standard protocols according to the 
manufacturer's instructions for the DNeasy Blood and Tissue Kit (Qiagen). 5’-
GGGGGGATCCTTCTGCAAAGGCCACCTACC-3’ and 5’-AGGGGAAGCTTCACT-
GTCCCCATTCTCAGC-3’ primers were synthesized for amplifying a 319-bp region of 
the PML gene (44157-44475 on GenBank accession number NG029036) with the CEM 
genomic DNA as template. Purified clones containing the insert were transformed into 
XL1-Blue cells and sequenced with M13 primers by Vantage (Vanderbilt Technologies 
for Advanced Sequencing.) pMP-bcr6 was linearized by treatment with Acc651. Terminal 
5′-phosphates were removed by treatment with calf intestinal alkaline phosphatase and 
replaced with [32P]phosphate using T4 polynucleotide kinase and [γ-32P]ATP. The DNA 
was treated with EcoRI, and the 2968-bp singly end-labeled fragment was purified from 
the small EcoRI−Acc651 fragment by being passed through a CHROMA SPIN+TE-100 
column (Clontech).  
 Reaction mixtures contained 1 nM labeled pMP-bcr6 and 60 nM wild-type human 
topoisomerase IIα or 115 nM catalytic core in 50 µL of DNA cleavage buffer (containing 
5 mM Ca2+) in the absence or presence of compounds. Reaction mixtures were incubated 
at 37 °C for 6 min, and enzyme−DNA cleavage complexes were trapped by the addition 
of 5 μL of 5% SDS followed by 4 µL of 250 mM EDTA (pH 8.0). Proteinase K (5 µL of 
a 0.8 mg/mL solution) was added, and samples were incubated at 45 °C for 30 min to 
digest the enzyme. DNA products were precipitated with ethanol and resuspended in 5 
µL of polyacrylamide gel loading buffer [10% agarose gel loading buffer, 80% 
formamide, 100 mM Tris-borate (pH 8.3), and 2 mM EDTA]. Samples were subjected to 
electrophoresis in denaturing 6% polyacrylamide sequencing gels. Gels were dried in 
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vacuo, and DNA cleavage products were visualized with a Bio-Rad Molecular Imager 
FX. 
 
Results and Discussion 
 
Recognition of Supercoil Geometry by Human Topoisomerase IIα 
Human type II topoisomerases can distinguish the handedness of DNA supercoils 
during scission and maintain levels of cleavage complexes with negatively supercoiled 
DNA that are ~2-4–fold higher than those seen with positively supercoiled molecules 
(Figure 9, left) (73). Several lines of evidence indicate that the C-terminal domain of 
topoisomerase II is not involved in this recognition (72, 73). Most notably, deletion of the 
C-terminal domain of human topoisomerase IIα does not affect the ability of the enzyme 
to preferentially cleave underwound molecules (72).  
 It is not clear which portion of topoisomerase IIα is responsible for the 
recognition of DNA geometry during cleavage. Although DNA cleavage is mediated by 
the catalytic core of the enzyme, rates of cleavage can be modulated by changes in the N-
terminal gate (24, 88) Therefore, the ability of the catalytic core of topoisomerase IIα to 
cleave negatively and positively supercoiled DNA was assessed. As shown in Figure 9 
(right), the catalytic core retained the ability to recognize supercoil handedness and 
preferentially cleaved negatively supercoiled plasmid.  
 The above experiments substituted Ca2+ for Mg2+ as the required divalent metal 
ion in order to generate levels of DNA cleavage that were high enough to reliably 
quantify enzyme-mediated DNA scission under conditions that did not include anticancer 
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Figure 9. The catalytic core of human topoisomerase IIα preferentially cleaves negatively 
supercoiled DNA in the presence of Ca2+. The ability of wild-type topoisomerase IIα 
(WT, left panel) and the catalytic core (CC, right panel) to cleave negatively [(-)SC, filled 
circles] or positively [(+)SC, open circles] supercoiled plasmid DNA is shown. Error bars 
represent the standard deviation of at least three independent experiments. 
WT CC 
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drugs (22). Previous work demonstrated that Ca2+ does not affect DNA cleavage site 
selection by topoisomerase IIα or the ability of type II enzymes to recognize DNA 
supercoil geometry (73, 89). Although the catalytic core displayed a preference for 
negatively supercoiled DNA that was similar to that of wild-type topoisomerase IIα 
(Figure 9), it exhibited unexpectedly high levels of DNA cleavage in the presence of 
Ca2+. The underlying basis for this high level of Ca2+-supported DNA cleavage is not 
known.  
 To further confirm the ability of the catalytic core to distinguish supercoil 
geometry, DNA cleavage was examined in the presence of Mg2+ and topoisomerase II 
poisons (Figure 10). Etoposide and the quinolone CP-115,953 are well-characterized 
interfacial poisons that do not intercalate into DNA (which would change the apparent 
topology of the plasmid substrate) (90, 91). Similar to results seen with Ca2+, the catalytic 
core maintained higher levels of cleavage complexes with negatively as compared to 
positively supercoiled DNA in the presence of Mg2+ and interfacial topoisomerase II 
poisons. 
 These results provide strong evidence that the ability to distinguish the geometry 
of DNA supercoils during cleavage is embedded in the catalytic core of human 
topoisomerase IIα. 
 
Role of the N-Terminal Gate of Topoisomerase IIα in Mediating Interactions with the T-
Segment of DNA 
Topoisomerase II binds negatively supercoiled DNA at sites of helix-helix 
crossovers, and it has been proposed that this ability to bind DNA crossovers allows 
topoisomerase II to distinguish between relaxed and supercoiled molecules (89, 92). 
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Figure 10. The catalytic core of human topoisomerase IIα preferentially cleaves 
negatively supercoiled DNA in the presence of etoposide and CP-115,953. The ability of 
wild-type topoisomerase IIα (WT, black) and the catalytic core (CC, red) to cleave 
negatively [(-)SC, filled circles] or positively [(+)SC, open circles] supercoiled plasmid 
DNA in the presence of etoposide (left panel) or CP-115,953 (right panel) is shown. 
Results for CP-115,953 are not shown at concentrations above 10 µM with the wild-type 
enzyme because the drug induced multiple cleavage events per plasmid. The inset shows 
cleavage induced by the catalytic core in the presence of 250 μM etoposide. Error bars 
represent the standard deviation of at least three independent experiments. 
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Although it has not been rigorously demonstrated, it is believed that the two DNA helices 
at the crossover become the G- and T-segments. 
 Studies with oligonucleotides indicate that binding of the T-segment greatly 
stimulates topoisomerase II-mediated cleavage of the G-segment (24, 93). These findings 
suggest that the T-segment plays an important role in the ability of topoisomerase II to 
identify and relax DNA supercoils. Although the N-terminal gate of the protein plays a 
critical role in capturing the T-segment and passing it through the DNA gate, it is not 
known whether the initial interaction with the T-segment is mediated by this portion of 
topoisomerase II or by the catalytic core of the enzyme. Therefore, we examined the 
ability of the catalytic core of topoisomerase IIα to cleave DNA that does not contain 
intrinsic crossovers. 
 In the first experiment, a linearized plasmid was used as the DNA substrate. 
Etoposide was included in experiments to increase levels of DNA scission. As seen in 
Figure 11, wild-type human topoisomerase IIα was able to cleave the DNA in the 
absence or presence of drug. Cleavage was enhanced when ATP was added to reaction 
mixtures. One interpretation of this finding is that in the presence of ATP, the N-terminal 
gate is able to capture the T-segment, thereby stimulating DNA scission. In contrast, the 
catalytic core of the enzyme was unable to cleave the linearized plasmid under any of the 
above conditions. Furthermore, no DNA cleavage was seen when the concentration of the 
catalytic core was increased 5-fold, or when Mg2+ was used in place of Ca2+ in reaction 
mixtures (not shown). These findings suggest that the N-terminal gate plays a critical role 
in mediating interactions with the T-segment. 
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Figure 11. Effects of etoposide on sites of DNA cleavage mediated by wild-type human 
topoisomerase IIα and the catalytic core. An autoradiogram of a polyacrylamide gel 
depicting DNA sites cleaved by wild-type topoisomerase IIα (WT) and the catalytic core 
(CC) is shown. Reaction mixtures contained no enzyme (DNA), enzyme in the absence 
of drug (No Drug), or enzyme in the presence of 20 μM etoposide with or without 1 mM 
ATP. Lanes shown were taken from different portions of the same gel. The 
autoradiogram is representative of three independent experiments. 
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 To further explore this conclusion, the ability of wild-type topoisomerase IIα and 
the catalytic core to cleave relaxed DNA was examined (Figure 12). In contrast to 
negatively supercoiled plasmid, which contains numerous inherent DNA crossovers, 
relaxed molecules contain few, if any intrinsic sites of helix-helix juxtaposition. For this 
reason, topoisomerase II preferentially cleaves negatively supercoiled over relaxed 
molecules (compare scission in Figures 10 and 12) (89). 
 Wild-type topoisomerase IIα was able to cleave relaxed plasmid (Figure 12, left), 
suggesting that the full-length enzyme can capture a transport-helix even when there are 
few intrinsic crossovers in the DNA substrate. When ATP was added to reaction 
mixtures, levels of cleavage increased ~9–fold (left), consistent with the conclusion that 
ATP induces closing of the N-terminal gate, stabilizing the capture of the T-segment. 
Although ATP also stimulates the ability of the intact enzyme to cleave negatively 
supercoiled plasmid (Figure 12, right), this enhancement is much smaller (~2–fold). The 
presence of high levels of helix-helix crossovers in the negatively supercoiled plasmid 
facilitates interactions between the intact enzyme and helix-helix crossovers, partially 
obviating the need for T-segment capture by the addition of ATP.  
 In contrast to topoisomerase IIα that contained its N-terminal gate, the catalytic 
core was unable to cleave relaxed plasmid in the absence or presence of ATP (Figure 12, 
left). Moreover, the addition of ATP did not enhance cleavage of negatively supercoiled 
plasmid (right).  
 These experiments lead to the conclusion that the catalytic core of human 
topoisomerase IIα cannot efficiently capture the T-segment. More importantly, they also 
lead to the conclusion that the N-terminal gate of the enzyme plays a critical role in 
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Figure 12. Effects of ATP on cleavage of relaxed and negatively supercoiled DNA by 
wild-type human topoisomerase IIα and the catalytic core. The ability of wild-type 
topoisomerase IIα (WT, black) and the catalytic core (CC, red) to cleave relaxed DNA 
(left panel) or negatively supercoiled DNA (right panel) in the presence of etoposide is 
shown. Experiments were carried out in the absence (filled symbols) or presence (open 
symbols) of 500 μM ATP. Experiments with negatively supercoiled DNA contained 50 
µM etoposide. Error bars represent the standard deviation of at least three independent 
experiments. Statistically significant difference is noted by an asterisk (*p < 0.01). 
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mediating the initial interaction with the T-segment. In the absence of this protein 
domain, the catalytic core is able to cleave supercoiled plasmid primarily because the 
substrate carries intrinsic DNA crossovers. Thus, the substrate is able to present the T-
segment to the enzyme, even in the absence of the protein domain that normally mediates 
the interaction with the second DNA double helix.  
 
Role of the N-Terminal Gate of Human Topoisomerase IIα in Mediating the Actions of 
Covalent Poisons 
A number of environmental, dietary, and medicinal compounds act as covalent 
topoisomerase II poisons (48, 50, 53-55, 57, 74, 75, 94-96). Compared to interfacial 
poisons, the mechanistic basis for the actions of covalent poisons is less well understood. 
These compounds form adducts with the enzyme (48, 50-53). At the present time, only 
cysteine adducts have been characterized. It has been proposed that the ability of covalent 
poisons to close the N-terminal gate plays an important role in mediating their ability to 
increase levels of topoisomerase II-DNA cleavage complexes (74, 75). However, 
modified residues have been identified in both the N-terminal gate and the catalytic core 
(51, 53). 
 In order to explore the role of the N-terminal gate in the actions of covalent 
poisons, the effects of benzoquinone (94) and thymoquinone (57) on DNA cleavage 
mediated by wild-type topoisomerase IIα and the catalytic core were examined. Effects 
on cleavage mediated by a truncated human enzyme lacking the C-terminal domain 
(hTop2α∆1175) also were determined as a control. Benzoquinone and thymoquinone 
displayed similar abilities to increase cleavage complexes formed with full-length 
topoisomerase IIα or hTop2α∆1175 and negatively supercoiled plasmid (Figure 13). This 
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Figure 13. Covalent poisons do not enhance DNA cleavage mediated by the catalytic core 
of human topoisomerase IIα. Effects of benzoquinone (left) and thymoquinone (right) on 
DNA cleavage mediated by wild-type human topoisomerase IIα (black), the catalytic 
core (red), and hTop2α∆1175 (blue) are shown. Error bars represent the standard 
deviation of at least three independent experiments. 
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finding demonstrates that the C-terminal domain plays no significant role in mediating 
the actions of covalent topoisomerase II poisons. In marked contrast, neither compound 
displayed any ability to enhance DNA cleavage mediated by the catalytic core. This 
result indicates that the N-terminal gate of topoisomerase IIα is critical for the actions of 
covalent poisons. Furthermore, it provides yet another distinction between interfacial 
poisons (which do not require the N-terminal gate to stimulate topoisomerase II-mediated 
DNA cleavage; see Figure 10) and covalent poisons. 
 In further contrast to interfacial poisons, covalent topoisomerase II poisons 
display the hallmark characteristic of inactivating the enzyme when the two are incubated 
prior to the addition of DNA (50, 94). Even though the inactivation can be explained by 
the ability of covalent poisons to close the N-terminal protein gate (thus preventing DNA 
from entering the active site of topoisomerase II) (51, 75), this proposed mechanism is 
controversial. Indeed, treatment of human topoisomerase IIα with benzoquinone or PCB 
quinones blocks the ability of the enzyme to cleave oligonucleotides that are able to bind 
to the protein and diffuse into the active site without entering through the protein gate 
(51). This finding implies that mechanisms besides the proposed closing of the N-
terminal gate may contribute to enzyme inactivation by covalent poisons. 
 To address this controversy, benzoquinone and thymoquinone were incubated 
with wild-type topoisomerase IIα, hTop2α∆1175, or the catalytic core prior to the 
addition of negatively supercoiled plasmid and the effects on DNA cleavage were 
assessed. Assays with the catalytic core were carried out in the presence of Ca2+ in order 
to raise baseline levels of DNA cleavage (see Figure 9). As seen in Figure 14, 
benzoquinone and thymoquinone inactivated all three enzymes. Thus, while covalent  
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Figure 14. Covalent poisons inactivate human topoisomerase IIα enzymes when 
incubated with the protein prior to the addition of DNA. The DNA cleavage activities of 
wild-type human topoisomerase IIα (black), the catalytic core (red), and hTop2α∆1175 
(blue) were monitored in the presence of 50 µM benzoquinone (left) or 50 µM 
thymoquinone (right). DNA cleavage levels were calculated relative to cleavage induced 
when the drug and the enzyme were not incubated prior to DNA addition. Error bars 
represent the standard deviation of at least three independent experiments. 
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poisons require the N-terminal gate in order to stimulate DNA cleavage mediated by 
topoisomerase II, they do not require this portion of the protein to inactivate the enzyme. 
Although the closing of the N-terminal gate may contribute to topoisomerase II 
inactivation, clearly other mechanisms can produce a similar effect. 
 
Mechanism of Action of Etoposide Quinone 
Etoposide has been linked to the generation of treatment-related acute myeloid 
leukemia (12, 42, 45, 46, 97), and etoposide quinone, a metabolite of etoposide (83, 98), 
has been implicated in this process (99). These leukemias feature rearrangements of the 
MLL gene at chromosomal band 11q23 and are believed to be triggered by drug-induced 
DNA cleavage events mediated by human type II topoisomerases (12, 42, 45, 46, 97). 
Although etoposide is an interfacial topoisomerase II poison, several studies indicate that 
etoposide quinone acts primarily as a covalent poison (84, 100, 101). However, it is not 
known whether the covalent interaction of the quinone with topoisomerase II masks the 
fact that the metabolite also can act as an interfacial poison.  
 Previous studies indicate that the pendant E-ring of etoposide is critical to its 
actions as an interfacial poison (Figure 15) (102-104). Substitution of either the 3’ or 5’ 
methoxy groups with a hydroxyl moiety has little effect on drug activity (100, 105). 
Thus, the catechol metabolite of etoposide displays an activity (and mechanism) similar 
to that of the parent drug. Removal of the 4’ hydroxyl moiety or substitution by a 
methoxy group greatly compromises the activity of etoposide (103, 104). However, it is 
not known whether substitution by a carbonyl group affects the ability of etoposide to 
function as an interfacial poison. 
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Figure 15. Etoposide quinone enhances DNA cleavage mediated by the catalytic core of 
human topoisomerase IIα. The effects of etoposide quinone on DNA cleavage mediated 
by wild-type human topoisomerase IIα (black), the catalytic core (red), and 
hTop2α∆1175 (blue) are shown. Cleavage reactions with etoposide quinone and the 
catalytic core that included 10 µM K3[Fe(CN)6] (open circles) also are shown. The 
structure of etoposide and the E-rings of etoposide catechol and etoposide quinone are 
depicted at right. Error bars represent the standard deviation of at least three independent 
experiments. 
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 The experiments shown in Figure 13 provide a method to determine whether 
etoposide quinone can function as an interfacial poison in addition to acting as a covalent 
poison. If etoposide quinone functions purely as a covalent poison, it should have no 
effect on DNA cleavage mediated by the catalytic core. However, if it retains the ability 
to act as an interfacial poison (despite the fact that it can also act as a covalent poison), it 
should display at least some activity against the catalytic core. As seen in Figure 15, 
etoposide quinone retains partial activity against the catalytic core of human 
topoisomerase IIα. It is possible that this activity reflects the fact that a portion of the 
etoposide quinone preparation has been reduced over time to the catechol, which is an 
interfacial topoisomerase II poison. To address this possibility, the effect of 10 µM 
K3[Fe(CN)6] on the ability of etoposide quinone to enhance DNA cleavage mediated by 
the catalytic core was assessed. The oxidant, which converts the catechol to the quinone 
(100), had little effect on the actions of etoposide quinone against the catalytic core. 
Although etoposide quinone functions primarily as a covalent topoisomerase II poison, 
these findings indicate that it still retains a modest ability to act as an interfacial poison of 
human topoisomerase IIα. 
 
Conclusions 
 The N-terminal gate and the catalytic core of type II topoisomerases work 
coordinately to capture, cleave, and transport DNA during the DNA strand passage 
reaction. Although this coordination is essential for proper enzyme function, it has 
obscured the individual contributions of these two domains to important aspects of 
enzyme–DNA interactions and drug mechanism. Previous studies have shown that the C-
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terminal domain of human topoisomerase IIα is responsible for DNA geometry 
recognition during relaxation; however, the present results indicate that the catalytic core 
is the portion of the enzyme that senses the handedness of DNA supercoils during the 
cleavage reaction (Figure 16). Conversely, the N-terminal gate plays critical roles in the 
capture of the T-segment.  
 The use of different topoisomerase IIα constructs also provided considerable 
insight into the actions of covalent topoisomerase II poisons (Figure 16). Whereas the N-
terminal gate is necessary for the enhancement of DNA cleavage by these compounds, 
residues within the catalytic core may be responsible for the inhibition of catalytic 
function that follows the incubation of covalent poisons with topoisomerase II prior to the 
addition of DNA. Finally, the ability of interfacial poisons, but not covalent poisons, to 
enhance DNA cleavage mediated by the catalytic core allowed us to further characterize 
the mechanism of action of etoposide quinone. Although this important drug metabolite 
functions primarily as a covalent poison, it still retains the ability to act in an interfacial 
manner. 
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Figure 16. Domains of human topoisomerase IIα and their involvement in DNA 
geometry recognition and drug activity. The enzyme is divided into three domains: the N-
terminal gate (blue, amino acid residues 1-430), which contains the ATPase active site; 
the catalytic core (red, residues 431-1193), which contains the TOPRIM domain (the 
portion that binds the catalytic divalent metal ions) and the DNA cleavage/ligation active 
site tyrosine residue (Y805); and the C-terminal domain (green, residues 1193-1531) (1, 
3, 4, 6, 8, 21, 22, 35). Functions associated with each domain are indicated. Three 
cysteine residues (C) are indicated in the N-terminal gate (C300, C392, and C405 from 
left to right). Cys300 has been identified as a site of attachment of isothiocyanate-based 
covalent topoisomerase II poisons (53). However, it has not been established whether 
attachment at this residue plays a role in the actions of these agents (53). Cys392 and 
Cys405 have been identified as sites of attachment of quinone-based covalent poisons 
(51), and substitution of alanine residues at these positions results in an ~2–fold 
resistance to a variety of covalent poisons (51, 55, 57).  
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CHAPTER III 
 
PRELIMINARY CHARACTERIZATION OF DNA GEOMETRY RECOGNITION BY 
BACILLUS ANTHRACIS GYRASE AND DRUG INTERACTIONS WITH THE 
BACTERIAL ENZYME 
 
Introduction 
 Globally, the bacterial chromosome is negatively supercoiled (it is ~6% 
underwound) (30). However, when helicases convert double-stranded to single-stranded 
DNA, they do so without unwinding the two plectonemically coiled strands of the double 
helix. Thus, in contrast to bulk DNA, the DNA immediately ahead of replication forks, 
transcription complexes, and other tracking systems is overwound (i.e., positively 
supercoiled) (30, 106). Because collisions with DNA tracking systems are critical for the 
conversion of transient topoisomerase-DNA cleavage complexes to permanent strand 
breaks, the cleavage complexes most likely to produce permanent strand breaks should be 
formed on overwound DNA (8, 107). Consequently, the ability of type II topoisomerases 
to cleave positively supercoiled DNA significantly impacts the potential response of cells 
to antibacterial drugs. 
 Previous studies indicate that human topoisomerase IIα and topoisomerase IIβ 
both are able to discern the geometry of DNA supercoils and maintain lower levels (~2– 
to 4–fold) of cleavage complexes with positively as compared to negatively supercoiled 
plasmids (73). Conversely, studies with E. coli topoisomerase IV suggest that this 
bacterial type II enzyme maintains higher levels of cleavage complexes with positively 
supercoiled molecules (33). 
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 Gyrase is believed to be the enzyme primarily responsible for removing positive 
supercoils ahead of DNA tracking systems in bacteria (1, 7, 30). However, at the present 
time, nothing is known about the effects of supercoil geometry on DNA cleavage 
mediated by gyrase or on the sensitivity of the enzyme to quinolone antibacterials. 
 As described in Chapter I, interactions of quinolones with topoisomerase IV are 
mediated through a water-metal ion bridge that is anchored by a highly conserved serine 
and an acidic residue located four amino acids away (Ser81 and Asp85 in B. anthracis 
gyrase, respectively) (19, 60, 61, 66-68). However, the role of the bridge appears to vary 
between species. Although B. anthracis topoisomerase IV uses the water-metal ion 
bridge as the primary mechanism to bind quinolones (19, 60, 66, 68), E. coli 
topoisomerase IV uses the bridge to properly align clinically relevant quinolones (67).  
Even though gyrase is the primary cellular target for quinolones in many bacterial 
species, including B. anthracis, the role of the water-metal ion bridge in mediating drug 
interactions has not yet been assessed. Alterations in the above conserved serine and 
acidic amino acid residues are the most common resistance mutations observed in gyrase 
from a multitude of species (19). Thus, it is highly likely that the water-metal ion bridge 
plays a critical role in coordinating quinolones and gyrase. However, the use of the bridge 
by gyrase has not yet been demonstrated and the role that the bridge plays in coordinating 
quinolone interactions remains an open question.  
In order to address the two issues described above, the ability of B. anthracis 
gyrase to discern supercoil geometry during DNA cleavage was assessed. Results 
indicate that like the human type II enzymes, both the wild-type bacterial enzyme and a 
common quinolone resistant mutant enzyme maintain lower levels of cleavage complexes 
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with positively supercoiled substrates. Finally, as a first step toward characterizing the 
role of the water-metal ion bridge in mediating quinolone interactions with gyrase, the 
sensitivity of wild-type and GyrAS85L gyrase to quinolones and quinazolinediones [a 
quinolone-like compound that does not require the bridge to interact with bacterial type II 
enzymes (60, 66, 68)] was assessed. The GyrAS85L mutant enzyme was utilized for these 
experiments because it is the most common mutation observed when selecting for 
quinolone resistant strains of B. anthracis in laboratory settings (108). Preliminary 
findings support the hypothesis that gyrase uses the bridge to coordinate quinolone 
interactions and lay the groundwork for future studies on this important mechanistic 
issue. 
  
Experimental Procedures  
 
Enzymes 
 B. anthracis gyrase enzymes were purified using the procedure of Dong et al. 
(109) with modifications. Genes encoding wild-type B. anthracis GyrA and GyrB were 
individually PCR-amplified from B. anthracis Sterne 34F2 chromosomal DNA and 
cloned into the pET15b (Novagen) expression vector, which provided an N-terminus 
6×His tag. Mutant quinolone-resistant GyrAS85L gyrase was generated by QuikChange 
(Stratagene) site-directed mutagenesis of the wild-type expression vector. Recombinant 
subunits were individually expressed in an E. coli BL21(DE3) ΔslyD strain. Cells were 
lysed by resuspension in CelLytic B (Sigma) containing protease inhibitors (Roche 
Complete Protease Inhibitor Cocktail, EDTA-free) and one passage through a French 
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press at 20,000 psi. The cell lysate was centrifuged at 20,000 × g for 30 min at 4°C to 
remove debris. The cleared lysate was incubated with 2 mL Ni-NTA agarose beads 
(Qiagen) for 1 h at 4°C with end-over-end rotation. Following batch binding, the beads 
were pelleted by centrifugation at 100 × g at 4°C and were then washed with a buffer 
containing 1 M NaCl, 60 mM imidazole, and 20 mM Tris-HCl (pH 7.9) for 30 min at 4°C 
with end-over-end rotation. Next, the beads underwent a series of four 1-min washes with 
a buffer containing 500 mM NaCl, 60 mM imidazole, and 20 mM Tris-HCl (pH 7.9). 
Finally, the beads were loaded into a column, and the proteins were eluted at 4°C with 12 
mL of a buffer containing 500 mM NaCl, 1 M imidazole, and 20 mM Tris-HCl (pH 7.9). 
Twelve 1-mL fractions were collected, and fractions 2-11 were combined, injected into a 
20kDa MWCO Slide-a-Lyzer dialysis cassette (Thermo), and dialyzed against 200 mM 
NaCl and 50 mM Tris-HCl (pH 7.5) at 4°C for 4 hours. The proteins were then dialyzed 
overnight at 4°C into 200 mM NaCl, 50 mM Tris-HCl (pH 7.5), and 20% glycerol and 
were subsequently stored at -80°C. Protein concentrations were determined by A280 
measurements, and the quality and purity of the subunits was determined by Coomassie 
staining following separation on a 7.5% SDS-PAGE gel. In all assays, gyrase was used as 
a 1:1 mixture of GyrA:GyrB. 
 
DNA Substrates 
 Negatively and positively supercoiled pBR322 plasmid DNA was prepared as 
described in Chapter II. 
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Drugs 
 Ciprofloxacin was obtained from LKT Laboratories and CP-115,953 was the gift 
of Thomas D. Gootz and Paul R. McGuirk (Pfizer). Both quinolones were stored at -20°C 
as a 40 mM stock solution in 0.1 N NaOH, and diluted five-fold with 10 mM Tris-HCl 
(pH 7.9) immediately prior to use.  Levofloxacin was obtained from Sigma-Aldrich and 
8-methyl-3’-(AM)P-quinazoline-2,4-dione was the gift of Dr. Robert Kerns (University 
of Iowa). These latter two compounds were stored at 4°C as 20 mM stock solutions in 
DMSO. 
 
Plasmid DNA Cleavage   
 DNA cleavage reactions were carried out using the procedure of Fortune and 
Osheroff (85). Reactions contained 250 nM wild-type or GyrAS85L mutant gyrase and 10 
nM negatively or positively supercoiled pBR322 in a total of 20 µL of 50 mM Tris-HCl 
(pH 7.5), 5 mM MgCl2, 100 mM potassium glutamate, 50 µg/mL bovine serum albumin, 
and 5 mM DTT. Reaction mixtures were incubated at 37°C for 30 min, and enzyme-
DNA cleavage complexes were trapped by the addition of 2 µL of 5% SDS followed by 2 
µL of 250 mM EDTA (pH 8.0). Proteinase K (2 µL of a 0.8 mg/mL solution) was added, 
and samples were incubated at 45°C for 45 min to digest the enzyme. Samples were 
mixed with 2 µL of agarose gel loading buffer, heated at 45°C for 5 min, and subjected to 
electrophoresis in 1% agarose gels in 40 mM Tris-acetate (pH 8.3) and 2 mM EDTA 
containing 0.5 µg/mL ethidium bromide. DNA bands were visualized and quantified as 
described above. DNA cleavage was monitored by the conversion of supercoiled plasmid 
to linear molecules.  
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Results and Discussion 
 
Recognition of Supercoil Geometry by Wild-Type B. anthracis Gyrase 
 As a first step toward analyzing the recognition of DNA geometry by gyrase, the 
effects of supercoil handedness on the level of DNA cleavage mediated by the wild-type 
B. anthracis enzyme were assessed in the presence of ciprofloxacin. The data shown in 
Figure 17 provide strong evidence that gyrase is able to discern the geometry of DNA 
supercoils. As was found with the human type II enzymes (73), gyrase maintained ~2–
fold lower levels of cleavage complexes when positively supercoiled (as opposed to 
negatively supercoiled) DNA was used as a substrate. Assays were carried out in the 
presence of ciprofloxacin in order to increase levels of DNA scission. However, as 
reflected in the zero ciprofloxacin data point, the enzyme is able to discern DNA 
geometry even in the absence of drug (a similar result can be seen in Figure 19). This 
conclusion recently has been confirmed by a more extensive study carried out by Rachel 
Ashley in the Osheroff laboratory. 
 The fact that gyrase maintains lower levels of cleavage complexes with positively 
supercoiled substrates contributes to the ability of the enzyme to alleviate torsional stress 
ahead of replication forks in a safe manner. However, it also renders gyrase an 
intrinsically less sensitive physiological target for quinolone antibacterial drugs. 
 
Characterization of GyrAS85L B. anthracis Gyrase 
 The most commonly observed quinolone resistance mutations occur in amino acid 
residues that are proposed to anchor the water-metal ion bridge. Consequently, the  
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Figure 17. Recognition of DNA geometry by B. anthracis gyrase during DNA cleavage 
in the presence of ciprofloxacin. DNA cleavage with negatively [(–SC), red circles] and 
positively [(+SC), blue circles] supercoiled DNA is shown. Error bars represent the 
standard deviation of three or more independent experiments. 
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characterization of these enzymes and their drug interactions has played an instrumental 
role in furthering our understanding of the role that the bridge plays in coordinating 
quinolone-based drugs. It also has provided tremendous insight into the basis of 
quinolone resistance and potential mechanisms for overcoming this drug resistance. 
 Although a series of structural and biochemical studies have provided a 
reasonable understanding of how the water-metal ion bridge affects quinolone 
interactions with topoisomerase IV (19, 60, 61, 66-68), parallel studies have yet to be 
carried out with gyrase. Therefore, a preliminary characterization of GyrAS85L B. 
anthracis gyrase was undertaken. GyrAS85L gyrase was used because it contains the most 
common quinolone resistance mutation observed in laboratory studies with B. anthracis 
(108). Note that Ser85 is homologous to the serine residue that has been shown to anchor 
the water-metal ion bridge in topoisomerase IV (61). 
 Because quinolones increase levels of enzyme-generated DNA cleavage 
complexes, these drugs depend on enzyme activity to support their function. Thus, if a 
mutation results in a loss of enzyme activity, it could cause quinolone resistance, even if 
it did not directly affect drug-enzyme interactions. Therefore, before characterizing the 
quinolone sensitivity of GyrAS85L gyrase, its intrinsic DNA cleavage activity was 
compared to that of the wild-type B. anthracis enzyme (Figure 18). The DNA cleavage 
activity of the mutant enzyme in the absence of drugs was actually somewhat higher than 
that seen with wild-type gyrase. A similar increase in DNA scission activity has been 
seen in resistance mutations at the equivalent residue in B. anthracis topoisomerase IV 
(66). Thus, quinolone resistance observed in cells carrying GyrAS85L gyrase is not due to a 
loss of enzyme activity. 
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Figure 18. DNA cleavage activity of wild-type and GyrAS85L B. anthracis gyrase. The 
activities of the wild-type (WT, blue bars) and GyrAS85L (S85L, red bars) mutant enzymes 
are shown. Error bars represent the standard deviation of three or more independent 
experiments. 
50    100   200   350   1000 
[Gyrase] (nM) 
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 In order to explore the mechanism of quinolone action and resistance, the next 
experiments examined the effects of drugs on DNA cleavage mediated by wild-type and 
GyrAS85L gyrase. Ciprofloxacin and levofloxacin, two clinically used quinolones, as well 
as CP-115,953, an experimental quinolone that displays high activity against bacterial 
and eukaryotic type II enzymes (91), were used for these studies. In addition, 8-methyl-
3’-(AM)P-quinazoline-2,4-dione, a quinolone-like drug that lacks the C3,4-keto acid 
required to chelate divalent metal ions, was used. This latter compound occupies the 
same interaction domain on topoisomerase IV as clinically relevant quinolones (110), but 
does not utilize the water-metal ion bridge (66). Rather, it interacts with the enzyme 
through novel contacts with its 3’-(AM)P moiety (68). 
 Although some differences in drug potency were noted, all of the compounds 
fundamentally had the same effect on wild-type B. anthracis gyrase and enhanced DNA 
cleavage >20–fold (Figure 19). In contrast, the quinolones displayed much lower activity 
against GyrAS85L gyrase. The two clinically used quinolones showed nearly no ability to 
enhance DNA cleavage and the potency of CP-115,953 was reduced considerably 
compared to its effects on wild-type gyrase (Figure 19). Despite the significant drop in 
activity seen with the quinolones, the quinazolinedione, which does not require a divalent 
metal ion, maintained the majority of its activity against GyrAS85L gyrase (Figure 19). 
These findings, although preliminary, strongly suggest that B. anthracis gyrase interacts 
with clinically relevant quinolones through the water-metal ion bridge. 
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Figure 19. Effects of quinolones and 8-methyl-quinazoline-2,4-dione on the DNA 
cleavage activities of wild-type and GyrAS85L B. anthracis gyrase. DNA cleavage 
mediated by wild-type (WT) GyrAS85L gyrase in the presence of drugs are shown in the 
left and right panels, respectively. Results with ciprofloxacin (blue circles), CP-115,953 
(green circles), levofloxacin (yellow circles), and 8-methyl-3’-(AM)P-quinazoline-2,4-
dione (Dione, red circles) are shown for the mutant enzymes. Error bars represent the 
standard deviation of three or more independent experiments. Structures of the drugs are 
shown above the graphs. 
[Compound] (µM) 
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Recognition of DNA Geometry by GyrAS85L B. anthracis Gyrase 
 The finding that GyrAS85L gyrase is still sensitive to 8-methyl-3’-(AM)P-
quinazoline-2,4-dione provided an opportunity to determine whether this common 
quinolone resistance mutation alters the ability of the enzyme to discern supercoil 
geometry during cleavage. As seen in Figure 20, the mutant enzyme retained its ability to 
recognize supercoil geometry and maintained lower levels of cleavage complexes with 
the positively supercoiled substrate. 
 
Conclusions 
 Although the ability of topoisomerase IV to discern supercoil geometry and 
utilize the water-metal ion bridge to coordinate quinolones has been examined (33), we 
know very little about these two critical issues for gyrase. The present chapter describes 
preliminary studies designed to address this deficiency. 
 Results indicate that B. anthracis gyrase can discern supercoil geometry and (like 
the eukaryotic type II enzymes) maintains lower levels of DNA cleavage complexes with 
positively supercoiled substrates. As discussed earlier, this makes gyrase a “safer” 
enzyme to act ahead of replication forks. However, it may decrease the ability of 
quinolones to enhance gyrase-mediated DNA cleavage in bacterial cells. Thus, it may 
have a negative impact on drug sensitivity. 
 Finally, preliminary studies with GyrAS85L gyrase strongly suggest that the B. 
anthracis enzyme interacts with quinolones through the water-metal ion bridge. This 
work sets the stage for more detailed future studies on gyrase. 
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Figure 20. Recognition of DNA geometry by wild-type and GyrAS85L mutant B. anthracis 
gyrase during DNA cleavage in the presence of 8-methyl-3’-(AM)P-quinazoline-2,4-
dione. DNA cleavage by wild-type (WT, circles) and GyrAS85L (S85L, squares) mutant 
gyrase with negatively [(–SC), red) and positively [(+SC), blue) supercoiled DNA is 
shown. Error bars represent the standard deviation of three or more independent 
experiments. 
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CHAPTER IV 
 
CONCLUSIONS 
 
 The work described in this dissertation has addressed a number of fundamental 
issues regarding the basis by which eukaryotic and bacterial type II topoisomerases 
recognize and interact with their DNA substrates and topoisomerase II poisons. Studies 
presented in Chapter II demonstrate that the ability of human topoisomerase IIα to 
discern supercoil geometry during DNA cleavage resides in the catalytic core of the 
enzyme. They also define new roles for the N-terminal domain in capturing the T-
segment of DNA during the strand passage reaction.  
 Chapter II demonstrates that covalent poisons require the N-terminal domain of 
topoisomerase IIα in order to enhance DNA cleavage. This finding is consistent with 
previous models for how covalent poisons function (74, 75). An intriguing result from the 
work in this chapter is the finding that covalent poisons do not require the N-terminal 
domain in order to inhibit enzyme activity when incubated with topoisomerase IIα prior 
to the addition of DNA. This finding strongly suggests that the ability of covalent poisons 
to increase or abrogate enzyme-mediated DNA cleavage (depending on the incubation 
conditions) results from different mechanisms. 
 Finally, the work presented in Chapter III, although preliminary in nature, adds 
substantially to our understanding of how gyrase recognizes and interacts with DNA and 
quinolones. This study lays the groundwork for detailed mechanistic studies. 
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Future Directions 
 The studies described above have opened several new vistas for the Osheroff 
laboratory. First, the finding that covalent poisons require the N-terminal domain of 
topoisomerase IIα to enhance enzyme-mediated DNA cleavage, but only require the 
catalytic core to inhibit enzyme function, provides strong evidence that our earlier 
“unified” theory for the actions of covalent poisons is incorrect. Therefore, the Osheroff 
laboratory plans to incubate the catalytic core of the enzyme with a variety of covalent 
poisons and determine the residues that may be responsible for the inhibitory activities of 
these compounds. One intriguing possibility is that covalent poisons adduct one or more 
active site amino acid residues when DNA is not present.   
 The work on the recognition of supercoil geometry by B. anthracis gyrase 
currently is being extended to DNA supercoiling reactions. Preliminary results indicate 
that the enzyme removes positive supercoils >10–fold faster than it generates negative 
supercoils in relaxed DNA. These findings suggest that gyrase may be an enzyme that 
was designed to function primarily on overwound molecules. It also raises the question of 
whether the conversion of positively supercoiled DNA to relaxed molecules by gyrase 
utilizes a different mechanism than the conversion of relaxed substrates to negatively 
supercoiled molecules.  
 Finally, given the importance of gyrase as a drug target, it is imperative to 
determine the basis by which quinolones interact with the enzyme. The preliminary 
studies described in Chapter III have set the stage for a detailed analysis of the role 
played by the water-metal ion bridge in mediating interactions of quinolone antibacterials 
with B. anthracis gyrase. These studies currently are underway. 
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